Empress Therapeutics

𝗛𝘆𝗽𝗲 𝗼𝗿 𝗛𝗼𝗽𝗲? Empress CSO Murray McKinnon, Ph.D., weighs in on whether he thinks AI is truly transforming drug development in this Pharma's Almanac Q&A. 🔗 https://lnkd.in/ezBER8hW #Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #drugdevelopment #pharma

If there’s a problem you care about, go solve it. That's the advice of Shannon McArdel, our Director of Immunology, whose mother's struggle with a progressive, debilitating disease motivated her to pursue a career in science. On International Day for Women and Girls in Science, she shares her journey and advice for those who also want to succeed in STEM. #TeamEmpress #IDWGS #CareersinSTEM #WomeninSTEM #WomenInScience

For #IDWGS, we chatted with automation engineer Kate Rooney from #TeamEmpress about how to empower current and aspiring female scientists. The robotics expert says mentorship is key for #WomeninSTEM. See what else she had to say in this short video for International Day for Women and Girls in Science. #CareersinSTEM #WomeninScience

What sparked Meryl Kelada's interest in science from an early age? Not only were both her parents doctors, but her grandmother, who was a biochemist, would share fascinating stories about her research and how she applied what she learned to everyday life. This made science feel both tangible and deeply meaningful. Meryl, who is a chemical biologist on our team, shared her thoughts for aspiring #WomenInScience for International Day for Women and Girls in Science. #TeamEmpress #IDWGS #CareersinSTEM #WomeninSTEM

🧧 恭喜发财 𝗛𝗮𝗽𝗽𝘆 𝗟𝘂𝗻𝗮𝗿 𝗡𝗲𝘄 𝗬𝗲𝗮𝗿 from #TeamEmpress, who came together this week to celebrate with our own mini money tree and treats. May the year ahead be healthy and prosperous for you all! 新年快樂 🐍

Medicine sourced in the context of a patient’s disease? It sounds simple, but it is anything but. Joseph Kelleher, Senior Vice President of Biology, talks to Drug Discovery News about how Empress is using AI and machine learning—anchored in human clinical data and genetic chemistry—to make unexpected connections to human diseases and clinical indications that were not previously appreciated. We do so by canvassing the 170,000,000 genes encoded in the microbes that co-evolved within our bodies, identifying the right molecules for the right targets, and synthesizing and optimizing them to derive drug candidates. 📚 Read the Q&A: https://lnkd.in/dfU-ZDgq #Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #microbiome

At the #FlagshipJPM CEO Chat, Empress CEO Jason Park shared how the company’s #Chemilogics platform is rewriting the rules of small molecule drug discovery. 🔬 Platform Differentiation: Empress combines genetics, co-evolution, AI, and synthetic biology to decode how DNA programs chemical synthesis. Starting with drug-like compounds already present in the body, we solve the key challenges of target identification, indication selection, and toxicology right from the start. ⚙️ Technology & Efficiency: With access to Nature’s “evolutionary database,” Empress has reduced drug discovery timelines to just two years from program conception to candidate. Leveraging human #metagenomics to find drug-like leads is faster and smarter. 💊 Pipeline Progress: Three first-in-class immunology programs are moving toward the clinic, with one already partnered. With hundreds of potential programs in the pipeline, 2025 promises big moves! 📈 Clinical Success: With a 50% in vivo success rate and clean tox profiles, Empress’ human-first data-driven approach has the potential to significantly reduce clinical development risks. 🤝 Teamwork: Backed by a powerhouse team that previously helped advance 30+ clinical programs and nine marketed products, Empress is focused on maximizing its pipeline's potential. Watch the short interview in the Flagship Pioneering Studios here: https://lnkd.in/gZS7suTM #JPM25 #FlagshipFounded #smallmolecule #drugdiscovery #geneticchemistry #AI #machinelearning #synbio

Nature has long been a master chemist, crafting solutions over millennia. At Empress Therapeutics, we harness this intelligence, combining it with AI and human insight to transform drug discovery. This synthesis of #polyintelligence, as beautifully articulated by Noubar Afeyan, inspires us daily. Explore how Empress embodies this vision in his annual letter for Flagship Pioneering. 🔗 Read more about polyintelligence including a case study on Empress here: https://lnkd.in/gfeax-7c  #JPM25 #FlagshipJPM #FlagshipFounded #SmallMolecule #DrugDiscovery #Chemilogics #AI #MachineLearning

2024 was a year of breakthroughs and bold strides at Empress. By leveraging the human metagenome to unlock nature’s evolutionary-scale database, we’ve set the stage for transformative drug discovery. This year, our pioneering platform delivered unprecedented advancements—accelerating timelines, uncovering novel targets, and redefining how medicines are made. We can’t wait for all we will achieve in 2025! 🚀 #DrugDiscovery #BiotechInnovation #Empress2024 #FutureOfMedicine #Chemilogics #FlagshipFounded

This holiday season, we’re toasting to the incredible team behind Empress Therapeutics!  🥂 We’re so proud to work alongside such innovative, passionate, and talented individuals. Here’s to a joyful holiday season and a groundbreaking year ahead!